Advertisement

Advanced Cell Technology Inc. is gaining an exclusive license to hemangioblast cell technology, for potential use in vascular repair, from a joint venture the Marlborough company formed with South Korea-based CHA Bio & Diostech Co Ltd. The venture, Stem Cell & Regenerative Medicine International (SCRMI), is shifting from a research entity to a licensing body, as both ACT and CHA Bio pursue hemagioblast cell developments.

As part of the deal, ACT will also add 10 SCRMI employees who were conducting research on differentiating human embryonic stem cells and induced pluripotent stem cells into hemangioblasts, which ACT chief scientific officer Robert Lanza noted in a press release could help carry red blood cells or platelets.

SOURCE

Advertisement
Advertisement